Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

ASCO 2022: Adjuvant Endocrine Therapy Plus Chemotherapy in Older Women With Breast Cancer
ASCO 2022: Long-Term Benefits of Denosumab Reported in Hormone Receptor–Positive Breast Cancer
Study Identifies Genetic Locus Potentially Linked to Treatment Response in Breast Cancer
ASCO 2022: Updated Safety Data From DESTINY-Breast03 on T-DXd Versus T-DM1 in Metastatic Breast Cancer
Do Diabetes and Glycemic Control Impact Outcomes in Patients With Metastatic Breast Cancer?
ASCO 2022: Endocrine Therapy Plus Ribociclib for CDK4/6 Inhibitor–Resistant Metastatic Breast Cancer
ASCO 2022: Novel HER3-Directed Antibody-Drug Conjugate Under Study in Metastatic Breast Cancer
ASCO 2022: Survival Update From PALOMA-2 With Palbociclib Plus Letrozole in Advanced Breast Cancer
ASCO 2022: Can Some Older Women With Breast Cancer Avoid Radiotherapy After Breast-Conserving Surgery?
ASCO 2022: DESTINY-Breast04 Reports Benefit of T-DXd in HER2-Low Metastatic Breast Cancer
ASCO 2022: TROPiCS-02 Meets Study Endpoint With Sacituzumab Govitecan-hziy in Advanced Breast Cancer
CDK Inhibition Plus Endocrine Therapy for Breast Cancer: Case Presentations
Novel Imaging Agent Under Study in Breast-Conserving Surgery: Focus on Intraoperative Margins
ASCO 2022: Survey Identifies ‘Actionable Steps’ to Diversify Clinical Trial Populations With Breast Cancer
Novel Triplet Under Study in Advanced Immunomodulatory Triple-Negative Breast Cancer
Declining Trend in Annual Mammography Among Breast Cancer Survivors, 12 Year-Analysis Reports
Leptomeningeal Metastasis of Breast Cancer: CSF Analysis May Improve Diagnosis and Treatment
Can Immune Checkpoint Inhibitors Improve Pathologic Complete Response in Breast Cancer?
Analyzing the Genomic Alteration Landscape of Invasive Micropapillary Breast Carcinoma
Fam-Trastuzumab Deruxtecan-nxki Receives FDA Approval in HER2-Positive Breast Cancer
Can Addition of T-DM1 Improve Outcomes Over Standard Treatment in HER2-Positive Breast Cancer?
Balancing Efficacy and Toxicity in Treatment Delivery in HER2-Positive Breast Cancer
AACR 2022: Therapeutic Implications of Genetic Insight Into Recurrence of Ductal Carcinoma In Situ
AACR 2022: What Can Be Learned From Man’s Best Friend About Aggressive Breast Cancer?
Does Extent of Surgery Impact Overall Survival for Younger Patients With Breast Cancer?
Are Positive Lymph Nodes an Indicator for Chemotherapy in Older Patients With Breast Cancer?
Compound From Cardamom Spice Under Study in Triple-Negative Breast Cancer
AACR 2022: Does Hormone Receptor–Positive ESR1-Mutated Breast Cancer Respond to CDK4/6 Inhibition?
FDA Brief: Cell-Based Immunotherapy Receives Fast Track Status in Metastatic Breast Cancer
MONALEESA-2 Trial: Overall Survival With Ribociclib Plus Letrozole in Advanced Breast Cancer
AACR 2022: Impact of Comorbidities on the Overall Health of Older Breast Cancer Survivors
ASBrS 2022: Study Finds COVID-19 Restrictions Delayed Care for Many Women With Breast Cancer
Nine High-Risk Breast Cancer Susceptibility Genes: What Can Be Learned From Them?
How Common Is Overdiagnosis of Breast Cancer in the United States?
Breast Cancer With Certain Pathogenic Variants: What Is the Optimal Approach to Screening?
Aromatase Inhibitors vs. Tamoxifen in Premenopausal Women With Breast Cancer
OlympiA Trial: Adjuvant Use of Olaparib Improves Survival in Early-Stage Breast Cancer With Germline BRCA Mutations
Trust Your Gut? Probiotic Supplementation and Cognition in Patients With Breast Cancer
Olaparib Approved by FDA for Adjuvant Treatment of High-Risk Early-Stage Breast Cancer
Breast Cancer in African American/Black Individuals: Trends in 2022
Do High MAPK4 Expression Levels Reduce the Sensitivity of TNBC to PI3K Blockade?
Is Daily Adjuvant Aspirin Use of Benefit in Preventing Disease Progression in Breast Cancer?
Pilot Trial Evaluates Mutation-Reactive TILs and Immunogenicity in Metastatic Breast Cancer
Live Cells Found in Human Milk May Advance Study of Breast Cancer Development
Expression of NDRG1: Prognostic Biomarker for Aggressive Breast Cancer?
Pyrotinib Versus Lapatinib in Combination Therapy for Metastatic Breast Cancer: Survival Update From PHOEBE Trial
Using Circulating Tumor DNA to Monitor Progression of Triple-Negative Breast Cancer
FDA Brief: Fast Track Designation Granted for Gedatolisib in Metastatic Breast Cancer
Patient Recall After Digital Breast Cancer Imaging: Do Fatigue and Experience of Radiologists Play a Role?
Do Patients With ESR1-Mutated Breast Cancer Benefit From Early Switch to Palbociclib Plus Fulvestrant?
Can Virtual Reality Improve Breast Magnetic Resonance Image Analysis?
Neratinib-Based Therapies for Metastatic and Triple-Negative Breast Cancers
Combining Fulvestrant With a CDK7 Inhibitor in Hormone Receptor–Positive Breast Cancer
Priority Review Granted by FDA to Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
mTOR1/2 Inhibitor Plus Fulvestrant Under Study in Metastatic Breast Cancer
FDA Brief: Fast Track Designation Granted to Enobosarm in Metastatic Breast Cancer
T-DXd Versus T-DM1 in Metastatic Breast Cancer: Subgroup Analyses From DESTINY-Breast03
How Does Pembrolizumab Impact the Tumor Microenvironment of Triple-Negative Breast Cancer?
How Useful Are Genomic Analyses for Patients With Metastatic Breast Cancer?
Advanced Breast Cancer: Overall Survival Subgroup Analysis From MONALEESA-2 Trial
Can Brain White Matter Microstructure Cause Cognitive Decline in Patients With Breast Cancer?


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.